EricCStrainMD

Addiction

Professor of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine; Section Head, JHB Psychiatry Substance Abuse Programs, Medical Director, Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Director, Center for Substance Abuse Treatment and Research

Join to view full profile

Dr. Strain is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Strain's full profile

Already have an account?

Office
4940 Eastern Ave
Baltimore, MD 21224
Phone+1 410-550-0018

Fax+1 410-550-0030

Education & Training

Johns Hopkins UniversityResidency, Psychiatry, 1984 - 1988
Ohio State University College of MedicineClass of 1984

Certifications & Licensure

MD State Medical License 1986 - 2025
American Board of Psychiatry and Neurology Psychiatry
American Board of Psychiatry and Neurology Addiction Psychiatry

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2007-2014
Top Doctors:Baltimore Area Castle Connolly, 2012

Clinical Trials

Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone Start of enrollment: 2002 Sep 01
Terminated
Not Applicable
Tryptophan and Behavior Therapy for Cocaine Abuse - 1 Start of enrollment: 1997 Mar 01
Completed
Phase 2
Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers Start of enrollment: 2000 Dec 01
Terminated
Not Applicable
Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence Start of enrollment: 2000 Dec 01
Completed
Not Applicable
Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence Start of enrollment: 1996 Aug 01
Completed
Not Applicable
Opioid Agonist and Antagonist Effects on Opioid Dependence Start of enrollment: 2004 Jan 01
Terminated
Phase 2
Fluoxetine to Reduce Cocaine Use in Cocaine and Opioid Addicts Start of enrollment: 2001 Apr 01
Completed
Not Applicable
Tramadol to Reduce Opioid Withdrawal Symptoms Start of enrollment: 2005 Feb 01
Completed
Phase 2
Abuse Potential of Buprenorphine/Naloxone Start of enrollment: 2004 Jun 01
Terminated
Phase 2
Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users Start of enrollment: 1997 Jan 01
Completed
Not Applicable
Assessment of Tramadol as a Treatment for Opioid Addiction Start of enrollment: 2006 Jan 01
Completed
Phase 1, Phase 2
Buprenorphine's Dose Response Curve Start of enrollment: 2007 Jan 01
Completed
Phase 2
The Discriminative Effects of Tramadol in Humans Start of enrollment: 2007 Nov 01
Completed
Phase 1, Phase 2
Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone Start of enrollment: 2008 Mar 01
Completed
Phase 2
Medications Development for Drug Abuse Disorders Start of enrollment: 2010 Oct 01
Completed
Phase 1, Phase 2
ABT-436 for Alcohol Dependence Start of enrollment: 2013 Feb 01
Completed
Phase 2
Treatment Engagement With Technology-assisted Treatment Start of enrollment: 2016 Feb 29
Completed
Not Applicable
An Innovative Intervention for OUD Treatment Start of enrollment: 2020 Nov 15
Recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

2 citations
Establishing a research agenda for the study and assessment of opioid withdrawal.
Kelly E Dunn, Eric C Strain
The Lancet. Psychiatry. 2024-07-01
1 citations
Suvorexant alters dynamics of the sleep-electroencephalography-power spectrum and depressive-symptom trajectories during inpatient opioid withdrawal.
Matthew J Reid, Kelly E Dunn, Liza Abraham, Jennifer Ellis, Carly Hunt
Sleep. 2024-04-12
Reply to "Capturing Synergy Holistically in Psychedelic Clinical Trials".
Robert H Dworkin, Michael P McDermott, Sandeep M Nayak, Eric C Strain
Clinical Pharmacology and Therapeutics. 2024-03-01

Press Mentions

Weed and Depression: Does Marijuana Make for Depressed Brains?September 30th, 2021
Effects of Psilocybin-Assisted Therapy on Major Depressive DisorderNovember 4th, 2020
Fighting the Opioid Crisis with Medication-Assisted TherapyMarch 14th, 2019
Join now to see all